Alkermes plc (ALKS) Tops Q1 EPS by 9c, Reaffirms Guidnce
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Alkermes plc Reports First Quarter 2015 Financial Results
April 30, 2015 7:00 AM EDTFirst Quarter Revenues of $161.2 Million and Non-GAAP Diluted EPS of $0.06
Late-Stage Pipeline Advancing Rapidly as Company Progresses Pivotal Programs for ALKS 5461 in Depression, ALKS 3831 in Schizophrenia and ALKS 8700 in Multiple Sclerosis
Preparing for Launch of Aripiprazole Lauroxil for Schizophrenia
2015 Financial Expectations Reiterated
DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) today... More
